US4774228A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polypeptide cartilage-inducing factors found in bone used in tissue proliferation
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1987-12-10
•
Granted: 1988-09-27
•
Expires: 2007-12-10
Abstract
Abstract Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-β assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-β whereas the other has an N-terminal sequence that is different from that of TGF-β derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.
Inventors
- 👤 Saeid Seyedin
- 👤 Thomas Thomas
- 👤 Hanne Bentz
- 👤 Larry Ellingsworth
- 👤 Rosa Armstrong
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:50
CPC Classifications
B; B64; B64C; B64C11/00; A; A61; A61K; A61K35/00; A61K35/12; A61K35/32; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/227; B65; B65B; B65B35/00; B65B35/30; B65B35/50; B65H; B65H31/00; B65H31/30; B65H31/3009; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/84; Y10S530/841; Y10S623/00; Y10S623/924; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
82 words
A method of promoting proliferation of soft tissue cells in an animal comprising administering a composition comprising (a) a polypeptide that (i) is active in the TGF-b assay; and (ii) is a dimer having a molecular weight of approximately 26,000 daltons as determined by SDS-PAGE, whose chains each have the following N-terminal sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp-; (b) a TGF-b activating agent; and (c) a pharmaceutically acceptable carrier, said polypeptide and activating agent being present in amounts that promote normal cell proliferation to the animal.
Claim 2
Independent Claim
82 words
A method of promoting proliferation of soft tissue cells in an animal comprising administering a composition comprising (a) a polypeptide that (i) is active in the TGF-b assay; and (ii) is a dimer having a molecular weight of approximately 26,000 daltons as determined by SDS-PAGE, whose chains each have the following N-terminal sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp-; (b) a TGF-b activating agent; and (c) a pharmaceutically acceptable carrier, said polypeptide and activating agent being present in amounts that promote normal cell proliferation to the animal.
Claim 3
Independent Claim
82 words
A method of promoting connective tissue deposition at a predetermined site in a patient comprising placing a composition comprising: (a) an effective amount of a polypeptide that (i) is active in the TGF-b assay; and (ii) is a dimer having a molecular weight of approximately 26,000 daltons as determined by SDS-PAGE, whose chains each have the following N-terminal sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp-; (iii) is free of effective amounts of TGF-b activating agent or chondrogenic co-factor; and (b) a pharmaceutically acceptable carrier at said site.
Claim 4
Independent Claim
82 words
A method of promoting connective tissue deposition at a predetermined site in a patient comprising placing a composition comprising: (a) an effective amount of a polypeptide that (i) is active in the TGF-b assay; and (ii) is a dimer having a molecular weight of approximately 26,000 daltons as determined by SDS-PAGE, whose chains each have the following N-terminal sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp-; (iii) is free of effective amounts of TGF-b activating agent or chondrogenic co-factor; and (b) a pharmaceutically acceptable carrier at said site.
References Cited (Backward Citations)
US3458397A
Cited
US4294753A
Cited
US4455256A
Cited
US4394370A
Cited
WO1984001106A1
Cited
US4434094A
Cited
EP0128849A1
Cited
US4563350A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-09-27 | 1992-03-28 | 1992-09-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-09-27 | 1996-03-28 | 1996-09-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-09-27 | 2000-03-28 | 2000-09-27 | $7700.00 | Window Closed / Lapsed |